J.P. Morgan projects the market for GLP-1 obesity medications could reach US$100 billion by 2030. On May 21, 2024 Nestlé unveiled Vital Pursuit, a 12-item line of portion-controlled frozen meals aimed at people taking GLP-1 drugs such as Ozempic and Wegovy. The meals are designed to be higher in protein and fibre and fortified with potassium, calcium and iron, and are due in grocery stores later in 2024; analysts point to the J.P. Morgan forecast and shifting portion sizes as the commercial rationale behind product changes across food makers and retailers.

J.P. Morgan's US$100 billion projection for the GLP-1 market by 2030 is reshaping how big food companies think about consumers' day-to-day meals. Nestlé's Vital Pursuit announcement on May 21, 2024 is the clearest example so far. The Swiss multinational described the offering as a companion for people taking GLP-1 agonists, a group of drugs that includes semaglutide-based therapies such as Ozempic and Wegovy.

Nestlé's bet: portion control and nutrients

Nestlé says Vital Pursuit will comprise 12 portion-controlled frozen meals formulated to be higher in protein and fibre. The line will include sandwich melts, pizzas and bowls made with whole grains or protein pasta, and the company says products will be fortified with nutrients such as potassium, calcium and iron that might be missed when people eat less overall. Nestlé's North America chief executive, Steve Presley, framed the project in the company's press release tied to the May 21 announcement, calling it "accessible, great-tasting food options that support the needs of consumers in this emerging category."

Nestlé said the Vital Pursuit meals will reach grocery stores later in 2024. Nestlé positioned the brand as distinct from legacy diet labels such as Lean Cuisine, pitching a different angle that focuses on nutrition balance rather than old-style dieting messages.

Retail analyst Neil Saunders, managing director at GlobalData Retail, described Nestlé's approach as a "much more scientific approach," saying the new brand emphasises nutrition and balance as GLP-1 drugs change portion sizes and meal frequency. That assessment reflects how food makers are adapting product design and marketing to the altered appetite profiles reported by many GLP-1 users.

Mastheads

Retail shake-up and the broader market

The Nestlé launch follows a string of moves by retailers and suppliers seeking to serve customers whose eating patterns have shifted. J.P. Morgan has estimated that roughly 9 percent of the U.S. Population could be on a weight-loss drug by 2030, a figure that has been widely cited in media coverage and corporate strategy discussions.

That projection is one reason companies from supplement chains to big-box stores are adjusting shelf space and services.

Health and consumption reporting notes that GLP-1 agonists mimic the hormone glucagon-like peptide 1, slowing gastric emptying and suppressing appetite. That mechanism leads many users to eat smaller portions and show less interest in high-calorie foods. Reporting also cited a Wegovy, semaglutide, study that both reduced cardiovascular risk and showed average weight-loss effects sustained up to 208 weeks in trial follow-up, a clinical backdrop companies reference when designing products for this cohort.

Not all of the market signals are uniformly sourced. Specific consumer-behaviour findings and recommended product responses such as packaging innovations, low-calorie formulation roadmaps and labelling strategies came from a food-industry commentary and a Mattson study cited only by NoonFoodNetwork.

Separately, an item in Chowhound quoted a Healthline figure that roughly one in eight Americans has tried a GLP-1 drug at least once. Those particular data points appear in single outlets in the set of coverage the industry is using to shape decisions.

Even so, the broad commercial logic is clear. As portion sizes shrink and meal timing changes for some consumers on GLP-1 drugs, packaged-food companies see opportunities to offer products that fit smaller appetites while still delivering protein, fibre and micronutrients. Nestlé's Vital Pursuit, with a mainstream price point, is a direct play for mainstream grocery shoppers as much as it's a specialised product for medication users.

How retailers allocate shelf space, how quickly competitors respond and whether consumers embrace a wave of targeted products will depend on how fast GLP-1 adoption continues and how persistent changes in taste and frequency prove to be. J.P. Morgan's 2030 projection remains the most commonly cited long-term benchmark for those decisions.

Related Articles

Nestlé says Vital Pursuit will appear in grocery stores later in 2024, marking a new front in the food industry’s commercial response to the projected US$100 billion GLP-1 market by 2030.

This article was created with AI assistance.